These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27277398)

  • 1. Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?
    Porpiglia F; Cantiello F; De Luca S; De Pascale A; Manfredi M; Mele F; Bollito E; Cirillo S; Damiano R; Russo F
    Int J Urol; 2016 Sep; 23(9):752-7. PubMed ID: 27277398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
    Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
    BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
    Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
    J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.
    Cantiello F; Russo GI; Cicione A; Ferro M; Cimino S; Favilla V; Perdonà S; De Cobelli O; Magno C; Morgia G; Damiano R
    World J Urol; 2016 Apr; 34(4):485-93. PubMed ID: 26194612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Epstein Criteria with Biopsy-Naïve Multiparametric Magnetic Resonance Imaging to Prevent Incorrect Assignment to Active Surveillance in the PI-RADS Version 2.0 Era.
    Fan Y; Zhai L; Meng Y; Chen Y; Sun S; Wang H; Hu S; Shen Q; Liu Y; Li D; Feng X; He Q; Wang X; Yu W; Jin J
    Ann Surg Oncol; 2018 Nov; 25(12):3510-3517. PubMed ID: 30225837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?
    Turkbey B; Mani H; Aras O; Ho J; Hoang A; Rastinehad AR; Agarwal H; Shah V; Bernardo M; Pang Y; Daar D; McKinney YL; Linehan WM; Kaushal A; Merino MJ; Wood BJ; Pinto PA; Choyke PL
    Radiology; 2013 Jul; 268(1):144-52. PubMed ID: 23468576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    Park JJ; Park BK
    J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
    Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
    J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.
    Thompson JE; van Leeuwen PJ; Moses D; Shnier R; Brenner P; Delprado W; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2016 May; 195(5):1428-1435. PubMed ID: 26529298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.
    Porpiglia F; DE Luca S; Passera R; Manfredi M; Mele F; Bollito E; DE Pascale A; Cossu M; Aimar R; Veltri A
    Anticancer Res; 2016 Sep; 36(9):4833-9. PubMed ID: 27630337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging.
    Song SH; Pak S; Park S; Song C; Jeong IG; Choi HJ; Kim JK; Cho KS; Kim CS; Ahn H
    J Urol; 2014 Aug; 192(2):402-8. PubMed ID: 24631106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
    Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy.
    Borkowetz A; Renner T; Platzek I; Toma M; Herout R; Baunacke M; Groeben C; Huber J; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2018; 100(2):155-163. PubMed ID: 29339663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
    Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
    AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?
    Diamand R; Albisinni S; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; An Nguyen T; Fournier G; Fiard G; Ploussard G; Peltier A; Roumeguère T
    Eur Urol Focus; 2023 Mar; 9(2):298-302. PubMed ID: 36210296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.